Pimecrolimus inhibits neuronal Aβ
Cell-based study · neurons derived from KhES-1 [1]
Pimecrolimus: inhibit Aβ in a dose-dependent manner without toxicity to the K1-derived neurons at concentrations of less than 10 μM.
| Endpoint | Reported result | Reference |
|---|---|---|
| Aβ40 | Reported result inhibit Aβ in a dose-dependent manner without toxicity to the K1-derived neurons at concentrations of less than 10 μM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 0.001, 0.01, 0.1, 1, and 10 μM
- Method
- cultured in neuron maintenance medium
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: LDN-193189 100 nM; SB431542 1 μM; cytosine arabinoside (AraC) 1 μM; brain-derived neurotrophic factor 10 ng/ml; glial cell-derived neurotrophic factor 10 ng/ ml; neurotrophin-3 10 ng/ml; beta-nerve growth factor 100 ng/mL. Compound effect isolated by the comparison: DMSO-treated PS1-G378E or K1 neurons.
- Reported limits
- Not stated in the sentences used: schedule.
Methods and source locations
Compound reported in the paper: Pimecrolimus
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > The screening of Aβ40 inhibitors using AD model neurons (S22); Methods > Cell culture and neural differentiation (S44, S45); Methods > Chemical screening (S48, S59); Figure 2 legend (S94, S97, S100); Figure 3 legend (S101)
Aβ40: Aβ40; comparator: DMSO-treated K1 neurons — Results > The screening of Aβ40 inhibitors using AD model neurons (S22); Figure 2 legend (S97)